GW Pharma's Cannabinoid Medicine Epidyolex Among CHMP Hopefuls
Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.
You may also be interested in...
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.
The European Medicines Agency’s drug evaluation committee, the CHMP, is this week considering products from Alexion Pharmaceuticals and Roche/Chugai Pharmaceutical who are both vying for a share of the as yet untapped EU market for neuromyelitis optica spectrum disorder.